lines, the concept that erythropoietin has activities unrelated to erythrodifferentiation. Sinclair and colleagues, based at Amgen, have published six papers since 2006 focused on whether the erythropoietin receptor (EPOR) is expressed by tumour cells-a fact that, if true, could have adverse effects for the use of erythropoietin in cancer. They conclude that EPOR is not expressed by many of the cells previously reported to express EPOR and exhibit cytoprotection by erythropoietin, and question the entire concept that erythropoietin is active on non-haemopoietic cells.
Although sometimes data from one laboratory are not replicated in another, many investigators have reported trophic or antiapoptotic effects of erythropoietin on many cells, including those that Sinclair and colleagues report in tabular form without presenting their original data. In fact, over the past 10 years, multiple investigators have shown that erythropoietin is tissue-protective, anti-inflammatory, and promotes neurogenesis and angiogenesis.
The observation that erythropoietin is neuroprotective in vivo 2 ignited substantial interest in its roles and possible therapeutic use in various diseases. Searching for "erythropoietin AND protect*", PubMed gives 863 hits of which we identified 346 research papers reporting a protective or reparative action, and only ten a lack of extra-haemopoietic effects.
Having no data to compare with previous studies, it is difficult to understand whether "inconsistent, irreproducible and at best modest (10-20%) effects" 1 refers to the inconsistency of the effect or to Sinclair and colleagues' experimental technique.
Sinclair and colleagues expand their conclusions further by stating that in vivo studies of erythropoietin in animal models of damage are faulty and that they "do not believe [that] clinical studies examining an alleged 'direct' effect of ESAs [erythropoiesis-stimulating agents] on heart or brain function or repair are well founded". 1 The term "alleged" is a hyperbole when referring to the tissue-protective actions of erythropoietin that, independently of the receptors implicated, are supported by hundreds of studies, two metaanalyses, 3 , 4 and some clinical trials, although we agree that caution should be used because of potential side-effects. 5 Cratylus, discussing with Plato, stated that names express the essence of the thing. This is hardly the case for cytokines: look at tumour necrosis factor or inter leukin 1. Although, from a pharmaceutical perspective, it would be convenient if erythropoietin had no activities outside erythropoiesis, this is wishful thinking. The field would be better served by efforts to understand the full spectrum of erythropoietin's actions.
